Terminated PHASE2 INTERVENTIONAL 2-arm NCT02855268

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome

Sponsor: Genzyme, a Sanofi Company

Conditions Alport Syndrome

Interventions Placebo lademirsen (SAR339375)

Updated 38 times since 2017 Last updated: Sep 10, 2025 Started: Nov 2, 2019 Primary completion: Sep 22, 2022 Completion: Sep 22, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The results of the futility analysis led to the study termination. No unexpected safety findings were identified.

Other terminated trials from Genzyme, a Sanofi Company

See all terminations from Genzyme, a Sanofi Company

This PHASE2 trial investigates Alport Syndrome and is currently terminated or withdrawn. Genzyme, a Sanofi Company leads this study, which shows 38 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

38 versions recorded

Oct 2025 — Present [monthly]

Terminated PHASE2
Sep 2025 — Oct 2025 [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Nov 2023 — Jul 2024 [monthly]

Terminated PHASE2

▶ Show 33 earlier versions

Nov 2022 — Nov 2023 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Jun 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE2
Mar 2022 — Jun 2022 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Jan 2022 [monthly]

Recruiting PHASE2
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2
May 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Apr 2021 — May 2021 [monthly]

Recruiting PHASE2
Mar 2021 — Apr 2021 [monthly]

Recruiting PHASE2
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE2
Sep 2020 — Oct 2020 [monthly]

Recruiting PHASE2
Jul 2020 — Sep 2020 [monthly]

Recruiting PHASE2
May 2020 — Jul 2020 [monthly]

Recruiting PHASE2
Apr 2020 — May 2020 [monthly]

Recruiting PHASE2
Mar 2020 — Apr 2020 [monthly]

Recruiting PHASE2
Feb 2020 — Mar 2020 [monthly]

Recruiting PHASE2
Dec 2019 — Feb 2020 [monthly]

Recruiting PHASE2

Status: Suspended → Recruiting
Aug 2019 — Dec 2019 [monthly]

Suspended PHASE2
Feb 2019 — Aug 2019 [monthly]

Suspended PHASE2
Jan 2019 — Feb 2019 [monthly]

Suspended PHASE2
Dec 2018 — Jan 2019 [monthly]

Suspended PHASE2

Status: Recruiting → Suspended
Jun 2018 — Dec 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Feb 2018 — May 2018 [monthly]

Recruiting PHASE2
Jan 2018 — Feb 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE2

Status: Active Not Recruiting → Recruiting
Nov 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE2
Feb 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genzyme, a Sanofi Company

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Beijing, China , Cleveland, United States , Cologne, Germany , Córdoba, Spain , Granada, Spain , Guangzhou, China , Göttingen, Germany , Herston, Australia , London, United Kingdom and 11 more locations